Vernakalant (oral) Prevention of Atrial Fbrillation Recurrence Post-Conversion Study

Cardiome Pharma Corp.0 个研究点目标入组 670 人开始时间: 2007年2月12日最近更新: 2012年3月19日

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Cardiome Pharma Corp.
入组人数: 670

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•- Comprehend and sign a written informed consent form, (per local and national regulations, as applicable);
•- Be 18 to 85 years of age;
•- Women must not be pregnant, be non-nursing and if pre-menopausal, must be using an effective form of birth control from time of screening until 3 months after the last dose of medication. Methods of birth control considered to be effective may include hormonal contraception (the pill), an intrauterine device (IUD), condoms in combination with a sprermicidal cream, total abstinence or sterilisation. Men should be advised not to conceive a child and are advised to use an effective form of birth control from admission until 3 months after the last dose of study medication;
•- Have symptomatic AF that has been sustained for greater than 72 hours and less than 6 months duration and is clinically indicated for cardioversion;
•- Have adequate anticoagulant therapy for cardioversion in accordance with standard of practice as recommended by ACC/AHA/ESC guidelines (Fuster V. et al, 2006);
•- Be haemodynamically stable (100 mmHg < systolic blood pressure < 190 mmHg) at screening and on Day 1 before dosing (while taking rate control drugs, if required). After resting supine for 3 minutes, blood pressures should be measured 3 times in 5 minutes with at least one minute between assessments;
•- Have a body weight between 45 and 113 kg (99 and 250 lbs).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•- Have known prolonged QT syndrome or QTcB interval of >0.500 sec as measured at screening on a 12-lead ECG; familial long QT syndrome; previous Torsades de Pointes; ventricular fibrillation; or sustained ventricular tachycardia (VT);
•- Have a QRS >0.140 sec;
•- Documented previous episodes of second or third-degree atrioventricular block;
•- Have clinically significant persistent bradycardia with ventricular rate below 50 beats/min, sick-sinus syndrome or pacemaker;
•- Have clinically significant moderate or severe aortic valvular stenosis (gradient >25 mmHg), hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis;
•- Have Class III or Class IV congestive heart failure at screening or admission, or have been hospitalized for heart failure in the previous 6 months;
•- Have a myocardial infarction (MI), cardiac surgery, angioplasty, unstable angina or acute coronary syndrome within 30 days prior to the entry into the study;
•- Have a serious pulmonary, hepatic, metabolic, renal (serum creatinine > 2.0 mg/dl), gastrointestinal, central nervous system (CNS) or psychiatric disease, end-stage disease states, or any other disease that could interfere with the conduct or validity of the study or compromise subject safety;
•- Have known concurrent temporary secondary causes of AF such as alcohol intoxication, pulmonary embolism, hyperthyroidism, pneumonia, hypoxemia (oxygen saturation < 90% on room air), acute pericarditis, or myocarditis;
•- Potassium (K+) <3.5 mmol/L or >5.5 mmol/L or magnesium (Mg2+) below the lower limit of normal (Mg2+ <0.65 mmol/L in subjects 65 years or younger and <0.80 mmol/L in subjects 66 years or older). (Both K+ and Mg2+ should be corrected prior to dosing);
•- Have a clinical evidence of digoxin toxicity;
•- Have received an oral Class I or Class III antiarrhythmic agent (including sotalol) within 3 days of randomisation or oral amiodarone within 4 weeks, or have received intravenous Class I or Class III antiarrhythmic agent or i.v. amiodarone within 24 hours prior to start of dosing;
•- Have any other surgical or medical condition that, in the judgement of the clinical Investigator might warrant exclusion or be contraindicated for safety reasons;
•- Be concurrently participating in another drug study or have received an investigational drug within 30 days prior to screening;
•- Be unable to communicate well with the investigator and to comply with the requirements of the entire study.

研究者

发起方

Cardiome Pharma Corp.

相似试验

进行中（未招募）

不适用

Vernakalant (oral) Prevention of Atrial Fbrillation Recurrence Post-Conversion Study

EUCTR2006-005072-40-CZCardiome Pharma Corp.670

进行中（未招募）

1 期

Vernakalant (oral) Prevention of Atrial Fbrillation Recurrence Post-Conversion StudyEstudio con Vernakalant (oral) para la prevención de las recurrencias de la fibrilación auricular después de la Cardioversió

EUCTR2006-005072-40-ESCardiome Pharma Corp.670

进行中（未招募）

不适用

Vernakalant (oral) Prevention of Atrial Fbrillation Recurrence Post-Conversion StudyAtrial fibrillation is the most common arrhythmia encountered in clinical practice. Atrial fibrillation is usually associated with age and general physical condition, rather than with a specific cardiac event. While not directly life-threatening, atrial arrhythmias can cause discomfort and can lead to stroke or congestive heart failure, and overall, increase morbidity.MedDRA version: 9.1Level: LLTClassification code 10066664Term: Recurrent symptomatic atrial fibrillation

EUCTR2006-005072-40-BECardiome Pharma Corp.670

进行中（未招募）

1 期

EUCTR2006-005072-40-BGCardiome Pharma Corp.670

进行中（未招募）

不适用

EUCTR2006-005072-40-PTCardiome Pharma Corp.670